MagForce, a pioneer in nanotechnology-based cancer treatments, is making steady progress with its strategy to drive the uptake of its thermal ablation treatment, NanoTherm. In Europe, NanoTherm is approved for glioblastoma (brain tumours) and while sales started slowly MagForce is seeing considerable growth in sales in 2020. Newly established treatment centres in Germany and Poland (with expansion to Italy and Spain expected in 2021), is driving an increasing number of glioblastoma patients trea ....
14 Oct 2020
MagForce - Striding towards major inflection points<a href="{filedir_2}DE000A0HGQF5magforce141020qv.pdf">DE000A0HGQF5magforce141020qv.pdf</a>
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MagForce - Striding towards major inflection points<a href="{filedir_2}DE000A0HGQF5magforce141020qv.pdf">DE000A0HGQF5magforce141020qv.pdf</a>
MagForce, a pioneer in nanotechnology-based cancer treatments, is making steady progress with its strategy to drive the uptake of its thermal ablation treatment, NanoTherm. In Europe, NanoTherm is approved for glioblastoma (brain tumours) and while sales started slowly MagForce is seeing considerable growth in sales in 2020. Newly established treatment centres in Germany and Poland (with expansion to Italy and Spain expected in 2021), is driving an increasing number of glioblastoma patients trea ....